Skip to main content
15 search results for:

ESMO 2020 conference hub (breast cancers) 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 24-09-2021 | ESMO 2021 | Conference coverage | Article

    Long-term effects of COVID-19 not uncommon in cancer patients

    The most common tumor type in the cohort was breast cancer (23.4%), followed by genitourinary and gynecologic cancers (19.3%).

  2. 02-10-2020 | ESMO 2020 | Conference coverage | Article

    PALLAS: No reduction in relapse risk with adjuvant palbociclib in early breast cancer

    The addition of palbociclib to adjuvant endocrine therapy does not prolong invasive disease-free survival in hormone receptor-positive, HER2-negative, stage II–III breast cancer, shows the phase 3 PALLAS trial.

  3. 06-10-2020 | ESMO 2020 | Conference coverage | Article
    News in brief

    pCR predicts 5-year survival for early-stage, HR-positive, HER2-positive breast cancer

    Pathologic complete response is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.

  4. 28-09-2020 | ESMO 2020 | Conference coverage | Article

    Neoadjuvant atezolizumab–chemotherapy improves TNBC pathologic response

    Combining atezolizumab with standard neoadjuvant chemotherapy achieves significantly higher pathologic complete response rates than chemotherapy alone in individuals with stage II–III triple-negative breast cancer, indicates the IMpassion031 trial.

  5. 22-09-2020 | ESMO 2020 | Conference coverage | Article

    monarchE: Adjuvant abemaciclib reduces relapse risk in high-risk early breast cancer

    Adding abemaciclib to adjuvant endocrine therapy significantly reduces the risk for recurrence in patients with high-risk, hormone receptor-positive, HER2-negative, early breast cancer, show phase 3 trial findings.

  6. 23-09-2020 | ESMO 2020 | Conference coverage | Article

    IMpassion131 rules out atezolizumab–paclitaxel duo in metastatic TNBC

    Adding atezolizumab to paclitaxel does not improve progression-free survival or overall survival in patients with unresectable locally advanced or metastatic triple-negative breast cancer, IMpassion131 data show.

  7. 20-09-2020 | ESMO 2020 | Conference coverage | Article

    IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

    The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

  8. 24-09-2020 | ESMO 2020 | Conference coverage | Article

    FLIPPER: Postmenopausal breast cancer patients benefit from first-line palbociclib–fulvestrant

    Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative, endocrine-sensitive, metastatic breast cancer, shows the phase 2 FLIPPER trial.

  9. 23-09-2020 | ESMO 2020 | Conference coverage | Article

    Sacituzumab govitecan boosts pretreated metastatic TNBC outcomes

    Previously treated patients with metastatic triple-negative breast cancer derive a significant survival benefit from treatment with sacituzumab govitecan versus standard single-agent chemotherapy, show phase 3 study data.

  10. play
    22-09-2020 | ESMO 2020 | Conference coverage | Video

    OS results from SOLAR-1 trial of alpelisib reported

    Fabrice André presents the overall survival data from the SOLAR-1 trial of alpelisib in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, and outlines the next steps for the further development of alpelisib and other PI3K inhibitors in this setting.

  11. play
    01-10-2020 | ESMO 2020 | Conference coverage | Video

    IMpassion130 and IMpassion131: The difference a taxane makes?

    Leisha Emens summarizes their IMpassion130 trial of atezolizumab and nab-paclitaxel in patients with advanced triple-negative breast cancer, and comments on the differences with the IMpassion131 study that instead used paclitaxel.

  12. play
    24-09-2020 | ESMO 2020 | Conference coverage | Video

    The ASCENT of sacituzumab govitecan in metastatic TNBC

    Aditya Bardia talks about the plans for the future development of sacituzumab govitecan following the positive results of the ASCENT trial in the metastatic triple-negative breast cancer setting.

  13. play
    29-09-2020 | ESMO 2020 | Conference coverage | Video

    monarchE and PALLAS: A tale of two CDK4/6 inhibitors

    George Sledge Jr speculates on the reasons for the contrasting results of the monarchE and PALLAS trials of adjuvant abemaciclib and palbociclib, respectively, in hormone receptor-positive, early-stage breast cancer.

  14. play
    20-09-2020 | ESMO 2020 | Conference coverage | Video

    Adjuvant palbociclib strikes out in PALLAS trial

    Erica Mayer explains why she believes the story of adjuvant palbociclib in hormone receptor-positive, HER2-negative, early-stage breast cancer is not yet over despite the failure of the PALLAS study to meet its primary endpoint.

  15. play
    20-09-2020 | ESMO 2020 | Conference coverage | Video

    IMpassion031 supports neoadjuvant atezolizumab in early TNBC

    Nadia Harbeck explains why the IMpassion031 results cement the role of neoadjuvant immunotherapy plus chemotherapy in early-stage triple-negative breast cancer.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.